Contact   |   Login

EquinYar™ Feed Supplements†

EquinYar™ feed supplements include the only formula in the global market for horses that is based on our proprietary and patent-protected strain of Yarrowia lipolytica yeast. Currently available yeast-based products in the market rely mainly on sugar-processing Saccharomyces cerevisiae yeast. All of our horse feed supplements that are based on EquinYar formula use fat as sources of carbon and energy, hence guaranteeing a higher content of valuable and bioavailable nutrients.

EquinYar™ feed supplements do

  • Strengthen immunity
  • Improve digestion
  • Increase strength and overall well-being
  • Strengthen hair and hoof horn,
  • Regenerate cells, and
  • Improve digestibility.

Among particularly high value nutrients provided by Yarrowia lipolytica yeast in the EquinYar formula are:

  • A full range of exogenous amino acids
  • Bioactive selenium in valuable organic complexes with sulphuric amino acids: selenomethionine and selenocysteine
  • Essential microelements, with particularly high content of zinc, manganese and cobalt
  • Macroelements that regulate electrolyte balance: calcium, sodium, potassium and chloride
  • Unsaturated fatty acids, including linoleic acid with its valuable omega-3 bonds
  • Vitamin B complex
  • Cytrulline maleate, alpha ketoglutarate and kynurenic acid

Catalog Download:

To download the latest catalog for EquinYar, click here.

Quick Contact

Catalog Download:
To download the latest catalog for EquinYar, click here.

Deferoxamine Mesylate Market to Witness Robust Expansion by 2029 with Teva api, Chengdu Easton Biopharmaceuticals, Pharmapex Group
The Deferoxamine Mesylate Report is a unique record that gives a total judgment of the market in terms of future patterns, development factors, creation volume, CAGR estimation, net revenue, cost, and industry-approved market data.

Pharmapex's novel mastitis treatment offers hope to world farmers
Efficient feed-based mastitis treatment boosts livestock health with a unique microencapsulated technology.

FDA approves Farxiga to treat type 2 diabetes
The U.S. FDA today approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
© , Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved.